...
meso-img

Mesoblast Ltd, Common Stock

MESO

NSQ

$16.76

+$4.51

(36.82%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$1.14B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
3.94M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
2.34
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.61 L
$13.74 H
$16.76

About Mesoblast Ltd, Common Stock

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameMESOSectorS&P500
1-Week Return61.54%-3.35%-2.97%
1-Month Return54.9%-3.49%-0.66%
3-Month Return161.47%-12.6%2.71%
6-Month Return133.1%-6.91%7.21%
1-Year Return690.57%1.19%23.04%
3-Year Return76.05%-0.21%28.43%
5-Year Return19.2%33.09%82.88%
10-Year Return-53.15%93.55%184.63%

Financials

Jun '20Jun '21Jun '22Jun '23Jun '245YR TREND
Total Revenue32.16M7.46M10.21M7.50M5.90M[{"date":"2020-06-30","value":100,"profit":true},{"date":"2021-06-30","value":23.19,"profit":true},{"date":"2022-06-30","value":31.75,"profit":true},{"date":"2023-06-30","value":23.33,"profit":true},{"date":"2024-06-30","value":18.35,"profit":true}]
Cost of Revenue25.31M32.72M30.76M27.73M15.72M[{"date":"2020-06-30","value":77.35,"profit":true},{"date":"2021-06-30","value":100,"profit":true},{"date":"2022-06-30","value":94,"profit":true},{"date":"2023-06-30","value":84.76,"profit":true},{"date":"2024-06-30","value":48.04,"profit":true}]
Gross Profit6.85M(25.26M)(20.55M)(20.23M)(9.81M)[{"date":"2020-06-30","value":100,"profit":true},{"date":"2021-06-30","value":-368.96,"profit":false},{"date":"2022-06-30","value":-300.07,"profit":false},{"date":"2023-06-30","value":-295.49,"profit":false},{"date":"2024-06-30","value":-143.35,"profit":false}]
Gross Margin21.29%(338.83%)(201.21%)(269.72%)(166.30%)[{"date":"2020-06-30","value":100,"profit":true},{"date":"2021-06-30","value":-1591.26,"profit":false},{"date":"2022-06-30","value":-944.98,"profit":false},{"date":"2023-06-30","value":-1266.72,"profit":false},{"date":"2024-06-30","value":-781,"profit":false}]
Operating Expenses107.56M115.06M90.78M76.79M5.90M[{"date":"2020-06-30","value":93.48,"profit":true},{"date":"2021-06-30","value":100,"profit":true},{"date":"2022-06-30","value":78.9,"profit":true},{"date":"2023-06-30","value":66.74,"profit":true},{"date":"2024-06-30","value":5.13,"profit":true}]
Operating Income(79.07M)(111.87M)(80.95M)(69.14M)(58.79M)[{"date":"2020-06-30","value":-7907200000,"profit":false},{"date":"2021-06-30","value":-11186700000,"profit":false},{"date":"2022-06-30","value":-8095300000,"profit":false},{"date":"2023-06-30","value":-6913600000,"profit":false},{"date":"2024-06-30","value":-5879400000,"profit":false}]
Total Non-Operating Income/Expense(23.00M)(1.25M)(28.30M)(32.10M)(48.19M)[{"date":"2020-06-30","value":-2299900000,"profit":false},{"date":"2021-06-30","value":-124800000,"profit":false},{"date":"2022-06-30","value":-2829700000,"profit":false},{"date":"2023-06-30","value":-3210300000,"profit":false},{"date":"2024-06-30","value":-4818700000,"profit":false}]
Pre-Tax Income(87.36M)(99.63M)(91.59M)(82.10M)(88.15M)[{"date":"2020-06-30","value":-8735500000,"profit":false},{"date":"2021-06-30","value":-9963000000,"profit":false},{"date":"2022-06-30","value":-9158600000,"profit":false},{"date":"2023-06-30","value":-8210100000,"profit":false},{"date":"2024-06-30","value":-8814700000,"profit":false}]
Income Taxes(9.41M)(819.00K)(239.00K)(212.00K)(191.00K)[{"date":"2020-06-30","value":-941500000,"profit":false},{"date":"2021-06-30","value":-81900000,"profit":false},{"date":"2022-06-30","value":-23900000,"profit":false},{"date":"2023-06-30","value":-21200000,"profit":false},{"date":"2024-06-30","value":-19100000,"profit":false}]
Income After Taxes(77.94M)(98.81M)(91.35M)(81.89M)(87.96M)[{"date":"2020-06-30","value":-7794000000,"profit":false},{"date":"2021-06-30","value":-9881100000,"profit":false},{"date":"2022-06-30","value":-9134700000,"profit":false},{"date":"2023-06-30","value":-8188900000,"profit":false},{"date":"2024-06-30","value":-8795600000,"profit":false}]
Income From Continuous Operations(77.94M)(98.81M)(91.35M)(81.89M)(87.96M)[{"date":"2020-06-30","value":-7794000000,"profit":false},{"date":"2021-06-30","value":-9881100000,"profit":false},{"date":"2022-06-30","value":-9134700000,"profit":false},{"date":"2023-06-30","value":-8188900000,"profit":false},{"date":"2024-06-30","value":-8795600000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-06-30","value":"-","profit":true},{"date":"2021-06-30","value":"-","profit":true},{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true}]
Net Income(77.94M)(98.81M)(91.35M)(81.89M)(87.96M)[{"date":"2020-06-30","value":-7794000000,"profit":false},{"date":"2021-06-30","value":-9881100000,"profit":false},{"date":"2022-06-30","value":-9134700000,"profit":false},{"date":"2023-06-30","value":-8188900000,"profit":false},{"date":"2024-06-30","value":-8795600000,"profit":false}]
EPS (Diluted)(0.74)(0.82)(0.70)(0.55)-[{"date":"2020-06-30","value":-74,"profit":false},{"date":"2021-06-30","value":-82,"profit":false},{"date":"2022-06-30","value":-70,"profit":false},{"date":"2023-06-30","value":-54.74,"profit":false},{"date":"2024-06-30","value":"-","profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

MESO
Cash Ratio 0.85
Current Ratio 1.18
Quick Ratio 1.15

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

MESO
ROA (LTM) -5.41%
ROE (LTM) -17.91%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

MESO
Debt Ratio Lower is generally better. Negative is bad. 0.28
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.72

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

MESO
Trailing PE NM
Forward PE 454.55
P/S (TTM) 241.90
P/B 2.97
EV/R 137.12
EV/Ebitda NM
PEG NM

FAQs

What is Mesoblast Ltd share price today?

Mesoblast Ltd (MESO) share price today is $16.76

Can Indians buy Mesoblast Ltd shares?

Yes, Indians can buy shares of Mesoblast Ltd (MESO) on Vested. To buy Mesoblast Ltd from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in MESO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Mesoblast Ltd be purchased?

Yes, you can purchase fractional shares of Mesoblast Ltd (MESO) via the Vested app. You can start investing in Mesoblast Ltd (MESO) with a minimum investment of $1.

How to invest in Mesoblast Ltd shares from India?

You can invest in shares of Mesoblast Ltd (MESO) via Vested in three simple steps:

  • Click on Sign Up or Invest in MESO stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Mesoblast Ltd shares
What is Mesoblast Ltd 52-week high and low stock price?

The 52-week high price of Mesoblast Ltd (MESO) is $13.74. The 52-week low price of Mesoblast Ltd (MESO) is $1.61.

What is Mesoblast Ltd price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Mesoblast Ltd (MESO) is

What is Mesoblast Ltd price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Mesoblast Ltd (MESO) is 2.97

What is Mesoblast Ltd dividend yield?

The dividend yield of Mesoblast Ltd (MESO) is 0.00%

What is the Market Cap of Mesoblast Ltd?

The market capitalization of Mesoblast Ltd (MESO) is $1.14B

What is Mesoblast Ltd’s stock symbol?

The stock symbol (or ticker) of Mesoblast Ltd is MESO

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top